Effectiveness of Acceptance and Commitment Therapy on the Positive and Negative Symptoms and Emotion Regulation of Patients with Schizophrenia Spectrum Disorders: A Single-case Clinical Trial Study

Hamid Khakbaz; Mohammad Saeed  Khanjani; Jalal  Younesi; Mohammad Reza Khodaie Ardakani; Mohammad Hadi Safi; Samaneh Hosseinzadeh

doi:10.5812/ijpbs-127419

Effectiveness of Acceptance and Commitment Therapy on the Positive and Negative Symptoms and Emotion Regulation of Patients with Schizophrenia Spectrum Disorders: A Single-case Clinical Trial Study

authors:

Hamid Khakbaz ¹ , Mohammad Saeed Khanjani ^{2
, *} , Jalal Younesi ² , Mohammad Reza Khodaie Ardakani ³ , Mohammad Hadi Safi ⁴ , Samaneh Hosseinzadeh ⁵

1 Student Research Committee, University of Social Welfare And Rehabilitation Sciences, Tehran, Iran

2 Department of Counselling, University of Social Welfare And Rehabilitation Sciences, Tehran, Iran

3 University of Social Welfare & Rehabilitation Sciences, Tehran, Iran

4 Department of Psychology, Faculty of Humanity & Social Sciences, Ardakan University, Ardakan, Iran

5 Department of Biostatistics, University of Social Welfare & Rehabilitation Sciences, Tehran, Iran

Iranian Journal of Psychiatry and Behavioral Sciences: Vol.16, issue 4; e127419

published online: October 22, 2022

article type: Research Article

received: May 2, 2022

revised: September 10, 2022

accepted: September 24, 2022

DOI: https://doi.org/10.5812/ijpbs-127419

how to cite: Khakbaz H, Khanjani M S , Younesi J , Khodaie Ardakani M R, Safi M H, et al. Effectiveness of Acceptance and Commitment Therapy on the Positive and Negative Symptoms and Emotion Regulation of Patients with Schizophrenia Spectrum Disorders: A Single-case Clinical Trial Study. Iran J Psychiatry Behav Sci. 2022;16(4):e127419. https://doi.org/10.5812/ijpbs-127419.

Abstract

Background:

The literature suggests the increasing application of acceptance and commitment therapy (ACT) for people with schizophrenia spectrum disorders (SSD).

Objectives:

This study aimed to determine the effectiveness of ACT on the positive and negative symptoms and emotion regulation of patients with SSD.

Methods:

The experimental design of the current study was an AB (baseline and intervention phases) along with the follow-up phase, in addition to Treatment-As-Usual (TAU), ACT sessions were held for the participants. Among the 20 participants who had inclusion criteria to the study, five participant (three men and two women in the age range of 32 - 43 years) were randomly allocated to participate in the intervention through drawing and evaluated using the Positive and Negative Syndrome Scale (PANSS) and Difficulties in Emotion Regulation Scale (DERS) in three phases of baseline, intervention, and follow-up. For data analysis, non-overlapping indices and Cohen's d effect size were measured, and visual diagrams were plotted for interpretation.

Results:

The present results showed that the effect sizes of psychotic symptoms in the first to fifth participants were 1.7, 1.9, 0.6, 4, and 1.4, respectively in the intervention phase relative to the baseline; the effect size was only large for the fourth participant. Also, the effect sizes of emotion regulation in the first to fifth participants were 0.8, 1.6, 1.5, 1.2, and 2.7, respectively; the effect size was only large for the fifth participant.

Conclusions:

The results of data analysis showed that ACT is effective in reducing psychotic symptoms and improving emotion regulation. The effect size of ACT was the largest for the fourth participant; medium for the first, second, and fifth participants; and small for the third participant.

Keywords

Acceptance and Commitment Therapy Emotion Regulation Psychotic Symptoms Schizophrenia

1. Background

Schizophrenia spectrum disorders (SSD) are characterized by psychotic symptoms (1) and emotional dysregulation (2). According to Cohen and Minor (3), negative emotions in patients with schizophrenia are associated with psychotic symptoms (4) and poor quality of life (5) and contribute to the formation and persistence of psychotic symptoms (6). The prevalence of SSD is approximately 3.5% in the general population (7), and the associated hospitalization rate is estimated at 25 to 38% (8).

Schizophrenia is one of the top ten causes of disability worldwide and is recognized as the most debilitating psychiatric disorder (9, 10). Frequent hospitalization in the acute phase of the disease increases the economic burden of SSD patients (11). Reduction of recurrence and prevention of readmission are among the treatment priorities for patients with Psychosis (12). The prevalence of SSD ranges from 05% and 0.6 to 0.89% in Iran, according to diagnostic criteria (13, 14), while Rahimi-Movaghar et al. reported a prevalence rate of 1% (15). Considering the population of Iran (over 86 million people), statistically, 765,400 people may suffer from psychotic symptom (16), which indicates the importance of psychological interventions.

The outcomes of medication use are often poor (17) and sometime maybe harmful for SSD patients (18), because clinically, they do not improve the patients’ cognitive symptoms significantly, and approximately 50% of patients do not respond to medications (19). Many therapies have been practiced for psychosis, such as psychoanalytic-psychodynamic therapy, systematic therapy, cognitive-behavioral therapy and its derivatives, combined approaches, and supportive psychotherapy (20) but the acceptance and commitment therapy (ACT) is a promising approach for filling this therapeutic gap for patients with psychiatric disorders (21). Although ACT has significant effects on the believability of auditory hallucinations, the impact of this approach on negative symptoms, delusional beliefs, and duration of therapeutic effects is unclear (22). For instance, White et al. used the ACT application along with TAU with a three-month follow-up for after psychosis emotional malfunctions in a randomized trial study. Minor progression in negative symptoms and considerable growth of improvement in mindfulness skills (23) were the outcomes of this therapy. Cramer et al. demonstrated that interventions based on short-period mindfulness, such as the ACT, have positive, but short effects on improvement of positive symptoms, duration of hospitalization, and concentration. They also are effective in supportive therapy for those suffering from psychosis (24). In a research called “ACT” and in an AB single-case study for hospitalized patients with psychosis, Larsson et al. (25) mentioned that this type of therapy is practical for them and can noticeably affect their quality of life. Furthermore, the patients themselves found ACT valuable.

For psychosis, ACT is commonly implemented in groups (26, 27). The less frequent use of single-case programs in psychiatry is due to a lack of knowledge of their practical value, not their usefulness (28). Accordingly, there are scares single-case studies on patients with SSD, and only one patient has been examined in some of these studies. Single-case studies are valuable for diagnosis, especially for psychiatric disorders (29), as well as development of appropriate therapies (30). Besides, ACT protocols for psychosis are still in their infancy and need to be revised (26). Khoury and Lecomte suggested performing ACT in at least eight sessions for inpatient with psychosis (31) and some experts suggested four sessions of the therapy (32), while in the present study, ACT was performed as a single-case intervention in 15 sessions for the following reasons: cost-effectiveness and assistance in the management of treatment costs in single-case projects for examining behavioral or educational interventions, besides the flexibility of single-case projects in different situations (33); assessment of the sustainability of intervention effects (34); and the limited number of single-case studies compared to group studies (27).

Although the effectiveness of ACT in reducing anxiety, believability of symptoms, and readmission has been investigated and its advantages have been observed in improving emotional symptoms, the reducing social damages, and distress related to hallucination (35), focusing on the emotional component and its role in maintaining psychotic symptoms is an important issue that should not be overlooked. Moreover, people with SSD may experience a recurrence of psychotic symptoms and emotional maladaptation throughout their lives. However, no study has been carried out to determine how people with SSD can move toward their life values through the ACT process following the alleviation of psychotic symptoms, improvement of emotion regulation, and reduction of psychotic symptoms.

2. Objectives

Considering the contradictions in the findings reported in the literature and the assumption that ACT is effective in correcting an individual’s perception of psychotic experiences and emotional dysregulation, this study aimed to determine the effectiveness of ACT on positive and negative psychotic symptoms and emotion regulation in patients with SSD.

3. Methods

3.1. Research Design

The experimental design of this AB single-case study included a follow-up phase, the initial sampling was accessible and without blinding. The statistical population consisted of all SSD patients, admitted to Razi Educational and Therapeutic Psychiatric Center in Tehran, Iran, in 2021. At the beginning, thirty patient were chosen accessibly for the research. Afterwards, 10 people were excluded due to the exclusion criteria. Among the 20 participants who had inclusion criteria to the study, five participant (three men and two women in the age range of 32 - 43 years) were randomly allocated to participate in the intervention through drawing. (Figures 1 and 2)

Figure 1.

Study design

Figure 2.

The CONSORT diagram

The sample in the present study was determined according to the minimum sample size required to confirm or reject research hypotheses in single-case designs. According to Horner and Odom (36), single-case designs could potentially provide a minimum number of intervention effects (i.e., changes between the baseline and intervention periods) if only three series were implemented. Nevertheless, they recommended that considering four series was better because conducting the study might face some problems (e.g., a participant may move to another city, or they may be hospitalized in other medical centers and need to be eliminated from the study). Thus, the sample size was determined at five participants.

The present article was extracted from a doctoral dissertation in rehabilitation counseling, approved by the Ethics Committee of Tehran University of Rehabilitation Sciences and Social Health (IR.UWSR.REC.1399.013). The present study was also registered in the Iranian Registry of Clinical Trials (IRCT20210412050937N1) on 07/22/2021 and performed at Razi Educational and Therapeutic Psychiatric Center, Tehran, Iran.

3.2. Participants

The inclusion criteria were as follows: (1) patients who diagnosed with SSD according to the psychiatrist diagnosis; (2) relative control of acute symptoms (those whose impulsivity and aggression are controlled according to their psychiatrist); (3) age range of 18 - 45 years; (4) voluntary participation and written informed consent of the patient and his/her legal guardian based on codes of professional ethics in the clinical trial ; (5) minimum education of high-school diploma; (6) hospitalization for at least one week in the ward; and (7) scores > 90 on the Positive and Negative Syndrome Scale (PANSS) and > 120 on the Difficulties in Emotion Regulation Scale (DERS). On the other hand, the exclusion criteria, accompanied by the psychiatrist and with reference to psychiatric cases of the patients and the diagnostic criteria, were as follows: (1) having of criminal or judicial problems; (2) severe learning disabilities (Patients who struggle to read, write and reason, and also to recall or organize information, based on their first interviews); (3) neurological disorders (Such as epilepsy, multiple sclerosis (MS), Parkinson’s disease (PD), and Alzheimer’s disease); (4) high levels of disordered behaviors or high risk of suicide or homicide; and (5) diagnosis of mental retardation (mental function or intelligence is lower than the average of society and compromising or poorly adaptive behaviors)

3.3. Research Tools

The PANSS, which contains 30 questions, was developed in 1986 by Kay et al. to measure the severity of positive and negative psychotic symptoms in patients with SSD. The alpha coefficients of the original version of PANSS were 73% and 83% for the positive and negative symptom subscales and 79% for the general pathology subscales, respectively (37). The Cronbach’s alpha coefficient of this scale was estimated at 80% in Iran (38) and 77%, and its validity was reported to be acceptable based on factor analysis (39, 40).

Moreover, Gratz and Roemer developed DERS. The reliability of this scale was estimated at 88% based on test-retest, and its internal consistency was 93% based on Cronbach's alpha (41). The final version of DERS contains 36 items. Asgari et al. reported the reliability of the Persian version of this scale to be 86% and 80% based on Cronbach's alpha coefficient and bisection method, respectively (42), and Mazloom reported a Cronbach's alpha coefficient of 85% (43).

3.4. Intervention and Its Implementation

The research protocol was based on a book, entitled “acceptance and commitment therapy and mindfulness for psychosis” (44). The intervention sessions were held in the counseling rooms of Razi Educational and Therapeutic Psychiatric Center in Shafa 1, Shafa 2, and Mehr 1 wards. The main ACT topics in the sessions were as follows: treatment logic, acceptance strategies, failure, self-identity, mindfulness exercises, compassion, clarification of values, previous unsuccessful attempts to deal with the symptoms of psychosis, alleviation of experiential avoidance, and coping with emotional distortions.

To reduce acute psychotic symptoms, mindfulness exercises were performed for 15 minutes in each session. Due to cognitive problems, fewer metaphors and abstract contents were used. In addition to ACT, the participants received their routine treatment (Pharmacotherapy and psychiatric services that patients receive after hospitalization and with the order of psychiatrist) at the hospital. They received ACT in 15 sessions (45 minutes per session) over eight weeks (The duration of the intervention sessions was conducted during eight weeks) after stabilization with medications (Consistency of the drug effects on patients’ acute psychotic symptoms or beginning of the intervention sessions after controlling the acute psychotic symptoms according to the patient’s psychiatrist’s diagnosis) and completed the PANSS and DERS in three baseline sessions, five intervention sessions, and two follow-up sessions (one month and three months after the intervention, respectively).

3.5. Statistical Analysis

Statistical analysis was performed using SPSS version 16 and Microsoft Excel. The research hypothesis was evaluated via visual analysis of graphs, non-overlapping indices, and Cohen's d effect size. In single-case studies, Ferguson reported values of 0.41, 1.1, and 2.7 for small, medium, and large effect sizes, respectively (45).

4. Results

4.1. Characteristics of the Participants

In this study, five participant, with a mean age of 38.4 years, participated in the ACT (SD = 2.6) (Table 1).

Table 1.

The Basic Information of SSD Patients

Participants	Age	Sex	Occupational Status	Marital Status	Education	Diagnosis
1	42	Female	Unemployed	Divorced	Diploma	Schizophrenia
2	38	Male	Employed	Single	Bachelor’s degree	Schizophrenia
3	36	Male	Non-governmental jobs	Married	Bachelor’s degree	Schizophrenia
4	36	Male	Non-governmental jobs	Single	Diploma	Schizophrenia
5	40	Female	Non-governmental jobs	Divorced	Diploma	Schizoaffective disorder

The participants’ mean and median scores of PANSS and DERS were slightly lower in the intervention and follow-up phases compared to the baseline (Table 2).

Table 2.

Distribution of PANSS and DERS Scores Following ACT in Three Phases of Baseline, Intervention, and Follow-up

Participants	A		B		Follow-up
Participants	Mean ± SD	Median	Mean ± SD	Median	Mean ± SD	Median
PANSS
1	100.3 ± 3.06	101	91 ± 6.04	90	90.5 ± 4.9	90.5
2	108 ± 1	108	97 ± 6.8	95	93.5 ± 4.9	93.5
3	103.6 ± 1.5	104	101.6 ± 4.04	102	102 ± 4.2	102
4	110.3 ± 1.5	110	98 ± 3.5	97	97 ± 2.1	97.5
5	115 ± 1	115	103.4 ± 9.5	102	95.5 ± 2.1	95.5
DERS
1	136 ± 2	136	133.6 ± 2.9	134	126.5 ± 3.5	126.5
2	135.6 ± 1.1	135	127.2 ± 6.05	125	124.5 ± 2.1	124.5
3	132 ± 2.6	131	128 ± 2.5	128	130.5 ± 3.5	130.5
4	129.3 ± 1.1	130	120 ± 9.2	121	110 ± 5.6	110
5	135 ± 2	135	120 ± 6.5	118	122 ± 2.8	122

Figures 3 and 4 indicate the trend of changes in the participants’ scores in the baseline, intervention, and follow-up phases.

Figure 3.

The participants’ PANSS scores in three baseline, intervention, and follow-up phases

According to Figure 3, the slope of change for the first, second, third, and fifth participants was slight and descending, indicating a reduction in the PANSS and DERS scores and small changes. However, in the fourth participant, the slope of the line was downward and steep; in other words, change occurred at a greater speed and to a greater extent.

Figure 4.

The participants’ DERS scores in the baseline, intervention, and follow-up phases

Table 3.

The Non-overlapping Indices and Effect Sizes of PANSS and DERS Scores in the Intervention Phase Compared to the Baseline Phase

Participant	NAP	PND	PAND	PEM	Cohen’s d Effect Size
PANSS
1	0.9	0.8	0.8	1	1.7
2	1	1	1	1	1.9
3	0.6	0.4	0.6	0.6	0.6
4	1	1	1	1	4
5	0.9	0.8	0.8	0.9	1.4
DERS
1	0.7	0.4	0.7	0.8	0.8
2	0.8	0.8	0.8	0.8	1.6
3	0.8	0.8	0.8	0.8	1.5
4	0.8	0.8	0.8	0.9	1.2
5	1	1	1	1	2.7

According to Table 3, the non-overlapping indices for the third participant in PANSS and for the first participant in DERS were small and medium, respectively, with a slight overlap, which suggests the small effect of the intervention. The non-overlapping indices for other participants showed moderate to high effects in both scales, suggesting moderate and high non-overlapping effects in the intervention phase compared to the baseline phase; in other words, the intervention had medium and high effect sizes.

Table 4.

The Non-overlapping Indices and Effect Sizes of PANSS and DERS Scores in the Follow-up Compared to the Intervention Phase

Participants	NAP	PND	PAND	PEM	Cohen’s d Effect Size
PANSS
1	0.5	0	0.7	0.5	0
2	0.6	0	0.7	0.5	0.5
3	0.4	0	0.7	0.5	0
4	0.5	0	0.7	0.5	0.1
5	0.7	0	0.7	1	0.9
DERS
1	0.9	0.5	0.8	1	2.2
2	0.6	0	0.7	0.5	0.4
3	0.2	0	0.7	0.2	0.9
4	0.8	0	0.8	1	1.1
5	0.3	0	0.7	0	0.3

According to Table 4, the percentage of non-overlapping data (PND) index was 0.0 for all participants in both scales (except for the first participant on DERS), which shows the percentage of follow-up phase points and suggests that the downward trend line in the follow-up phase did not continue and that the scores of the two scales were higher in the follow-up (a small non-overlapping effect). The other three indices were small, medium, and high, suggesting small, medium, and large non-overlapping effects in the intervention phase compared to the baseline phase, respectively. The discrepancy between these values is attributed to differences in calculations and the greater number of observations in the intervention phase compared to the follow-up, which suggests a greater non-overlapping effect. Therefore, among the evaluated indices, the PND index presented a more accurate comparison.

5. Discussion

This study aimed to determine the effectiveness of ACT on positive and negative symptoms and emotion regulation in patients with SSD. It was performed for the first time as a single-case study on five participant in Razi Educational and Therapeutic Psychiatric Center, and the results showed the effectiveness of ACT in reducing psychotic symptoms and improving emotion regulation. Although these results are inconclusive, and many factors may play a role in the patient's recovery (including TAU), ACT is an effective therapeutic intervention to provide psychological services to patients with SSD. Also, differences between the PANSS and DERS scores in the intervention and follow-up phases indicated small to medium effect sizes.

Considering the mean PANSS scores in the baseline, intervention, and follow-up phases, the rate of psychotic symptoms decreased in patients to some extent. Although the purpose of ACT is not to reduce the symptoms of psychosis, these changes may be one of its outcomes (46). Regarding the relationship between experiential avoidance and hallucinations (26) and delusions (47), it seems that ACT can change the patient's relationship with the symptoms rather than the symptoms themselves. The results are consistent with the findings of study by Yildiz (48). Since SSD patients suffer from symptoms, such as depression, anxiety, and hallucinations, it seems that ACT can first reduce the psychological stress of hallucinations and then decrease the symptoms of psychosis and emotional dysregulation.

Consistent with the findings of the present study, Shawyer et al. (26) found that ACT had moderate effects on psychotic symptoms. Considering the effect of ACT on stress caused by hallucinations, it seems that ACT improves the patient's emotion regulation after reducing stress, which is effective in reducing their psychotic symptoms. In the present study, ACT had small and moderate effects on psychosis symptoms and emotion regulation, respectively by reducing stress caused by psychotic symptoms and emotion dysregulation; nonetheless, this study had a single-case design.

Regarding the decline in the mean DERS scores, the results of the present study are consistent with the findings of previous studies conducted by White et al. (23), Louise et al. (49), and Villatte et al. (50), which suggested a reduction in emotional dysregulation caused by psychosis and acceptance of emotions. The ACT possibly encouraged patients to move toward their life values and goals by helping them accept their painful mental experiences; this played an important role in their emotional functioning. According to these findings, ACT was effective in improving the patients’ emotional regulation.

Based on the scores of the first, second, fourth, and fifth participants in the intervention phase compared to the baseline phase, the scores of psychotic symptoms and emotional dysregulation decreased compared to the baseline phase, which shows the low to moderate effectiveness of ACT. Also, the first, third, and fourth participants obtained low scores on PANSS in the follow-up, and the scores of the second and fifth participants showed a moderate effect size; in other words, ACT had small and moderate effects on the symptoms of psychosis. Considering the relationship between anxiety reduction and cognitive defusion (51), it seems that ACT, by using failure strategies, such as conscious observation of psychiatric experiences, reduces the stress caused by the symptoms and then diminishes psychotic symptoms and improves emotion regulation. Although it is not clear if cognitive defusion is effective in reducing the symptoms, this study showed that ACT could offer effective strategies, such as acceptance and non-judgment, distancing, and isolation from psychotic experiences.

Tyrberg et al. (52) and White et al. (23) showed that people with psychosis can follow their personal values by attending ACT sessions. However, the average number of ACT sessions in their study was two sessions, while in the present study, 15 ACT sessions were held. Based on the findings, although all participants experienced psychotic symptoms constantly, commitment to therapeutic homework appeared to be effective in reducing psychotic symptoms and improving emotion regulation. By using mindfulness and emotion acceptance, ACT seems to help patients view their treatment as a rewarding experience; this result is consistent with the findings of a study by Spidel et al. (27). This result is of great significance owing to the role of emotion regulation in an individual’s functioning and psychotic symptoms (31). Although ACT may be helpful for SSD patients, any conclusions regarding the effectiveness of ACT for this group should be made with caution. Therefore, further research is needed to replicate our findings using a larger sample size and group therapy and compare the findings with a control group.

The most important limitation of the present study is that due to the COVID-19 epidemic, sampling and testing were performed under strict observance of health protocols. Therefore, it is recommended to perform ACT in a group for people with SSD in psychiatric and mental health centers in case of reduction of the coronavirus disease epidemic. Also, not checking negative symptoms, small sample size, and limited generalizability of the findings made it difficult for us to reach definite conclusions. On the other hand, the strengths of this study include exclusive, patient-centered treatment, collaboration with other therapists (e.g., psychiatrists, psychologists, nurses, social workers and counsellors), and initiation of treatment after control of acute psychotic symptom with medications.

5.1. Conclusions

The application of the ACT may be an appropriate and valuable additive for reducing the psychotic symptoms and improving the emotional regulation of the people with schizophrenia in psychiatric and mental health centers. It can play a valuable role in the mental health of SSD patients by changing their attitude towards psychotic symptoms and improving their emotion regulation. Replication of this study in the future can provide promising results for the establishment of ACT in psychiatric wards. It seems that ACT is a suitable option for psychologists, psychiatrists, nurses, and paramedics working, counsellors, mental health experts and other clinical professionals working in Educational, Therapeutic and Rehabilitation Psychiatric Centers.

5.2. Highlights

The ACT plays an effective role in reducing the positive and negative symptoms of SSD patients and improving their emotional regulation.

Acknowledgements

Footnotes

Authors' Contribution: Study concept and design: H.K and M.S.K and S.J.Y; Acquisition of data: H.K and S.H and M.R.K.A; Analysis and interpretation of data: H.K and S.H and M.S.K; Drafting of the manuscript: H.K and M.S.K and S.J.Y and M.R.K.A and M.H.S ; Critical revision of the manuscript for important intellectual content: M.R.K.A and M.H.S; Statistical analysis: S.H and H.K; Administrative, technical, and material support: M.S.K and S.J.Y; Study supervision: M.S.K and S.J.Y..
Clinical Trial Registration Code: IRCT20210412050937N1 (ClinicalTrials.gov/IRCT20210412050937N1) https://fa.irct.ir/user/trial/55742/view
Conflict of Interests: Write in detail about the below items within the last five years: Funding or Research support: This study was performed in Razi Psychiatric Educational, Research and Treatment Center and this center is under the supervision of the University of Social Welfare and Rehabilitation Sciences. Employment: Authors can use the facilities of Razi Psychiatric Educational, Research and Treatment Center for free. Personal financial interests: Authors can use the facilities of Razi Psychiatric Educational, Research and Treatment Center for free. Stocks or shares in companies: Razi Psychiatric Educational, Research and Treatment Center is under the supervision of the University of Social Welfare and Rehabilitation Sciences. Consultation fees: No fee was received from the participants, the fee is received by the center and we have no benefit in this regard. Patents: No. Personal or professional relations with organizations and individuals (parents and children, wife and husband, family relationships, etc.): There were no personal relationships in this study. Unpaid membership in a government or non-governmental organization: No fee was charged for the study. Are you one of the editorial board members or a reviewer of this journal? No.
Data Reproducibility: The dataset presented in the study is available on request from the corresponding author during submission or after its publication. The data are not publicly available due to Due to the observance of the principles of confidentiality and ethics for patients with schizophrenia.
Ethical Approval: This study is approved under the ethical approval code of IR.USWR.REC.1399.013 (webpage of ethical approval code is: ethics.research.ac.ir/EthicsProposalView.php?id=128795)
Funding/Support: This study has no scholarships, training or research grants.

References

1.
Galderisi S, Kaiser S, Bitter I, Nordentoft M, Mucci A, Sabe M, et al. EPA guidance on treatment of negative symptoms in schizophrenia. Eur Psychiatry. 2021;64(1). e21. [PubMed ID: 33726883]. [PubMed Central ID: PMC8057437]. https://doi.org/10.1192/j.eurpsy.2021.13.
2.
Ludwig L, Werner D, Lincoln TM. The relevance of cognitive emotion regulation to psychotic symptoms - A systematic review and meta-analysis. Clin Psychol Rev. 2019;72:101746. [PubMed ID: 31302506]. https://doi.org/10.1016/j.cpr.2019.101746.
3.
Cohen AS, Minor KS. Emotional experience in patients with schizophrenia revisited: meta-analysis of laboratory studies. Schizophr Bull. 2010;36(1):143-50. [PubMed ID: 18562345]. [PubMed Central ID: PMC2800132]. https://doi.org/10.1093/schbul/sbn061.
4.
Macfie WG, Spilka MJ, Bartolomeo LA, Gonzalez CM, Strauss GP. Emotion regulation and social knowledge in youth at clinical high-risk for psychosis and outpatients with chronic schizophrenia: Associations with functional outcome and negative symptoms. Early Interv Psychiatry. 2022. [PubMed ID: 35362242]. https://doi.org/10.1111/eip.13287.
5.
Gardsjord ES, Romm KL, Friis S, Barder HE, Evensen J, Haahr U, et al. Subjective quality of life in first-episode psychosis. A ten year follow-up study. Schizophr Res. 2016;172(1-3):23-8. [PubMed ID: 26947210]. https://doi.org/10.1016/j.schres.2016.02.034.
6.
Hartley S, Barrowclough C, Haddock G. Anxiety and depression in psychosis: a systematic review of associations with positive psychotic symptoms. Acta Psychiatr Scand. 2013;128(5):327-46. [PubMed ID: 23379898]. https://doi.org/10.1111/acps.12080.
7.
Perala J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsa E, Pirkola S, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007;64(1):19-28. [PubMed ID: 17199051]. https://doi.org/10.1001/archpsyc.64.1.19.
8.
Wheeler A, Robinson E, Robinson G. Admissions to acute psychiatric inpatient services in Auckland, New Zealand: a demographic and diagnostic review. N Z Med J. 2005;118(1226):U1752. [PubMed ID: 16311610].
9.
Ajinkya SA, Jadhav PR, Rajamani S. Which is A More Debilitating Disorder Schizophrenia or Dysthymia? - A Comparative Study. J Clin Diagn Res. 2015;9(5):VC01-3. [PubMed ID: 26155539]. [PubMed Central ID: PMC4484131]. https://doi.org/10.7860/JCDR/2015/11935.5926.
10.
Alqahtani A, Kay ES, Hamidian S, Compton M, Diab M. A Quantitative and Qualitative Analysis of Schizophrenia Language. arXiv preprint arXiv:2201.10430. 2022.
11.
Fu AZ, Pesa JA, Lakey S, Benson C. Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia. BMC Psychiatry. 2022;22(1):1-10. [PubMed ID: 35395757]. [PubMed Central ID: PMC8994268]. https://doi.org/10.1186/s12888-022-03895-2.
12.
Gaudiano BA, Davis CH, Epstein-Lubow G, Johnson JE, Mueser KT, Miller IW. Acceptance and Commitment Therapy for Inpatients with Psychosis (the REACH Study): Protocol for Treatment Development and Pilot Testing. Healthcare (Basel). 2017;5(2). [PubMed ID: 28475123]. [PubMed Central ID: PMC5492026]. https://doi.org/10.3390/healthcare5020023.
13.
Taheri Mirghaed Masood, Abolghasem Gorji Hasan, Panahi Sirous. Prevalence of Psychiatric Disorders in Iran: A Systematic Review and Meta-analysis. Int J Prev Med. 2020;11:64. [PubMed ID: 32175061]. [PubMed Central ID: PMC7050223]. https://doi.org/10.4103/ijpvm.IJPVM_510_18.
14.
Noorbala AA, Faghihzadeh S, Kamali K, Bagheri Yazdi SA, Hajebi A, Mousavi MT, et al. Mental Health Survey of the Iranian Adult Population in 2015. Arch Iran Med. 2017;20(3):128-34. [PubMed ID: 28287805].
15.
Rahimi-Movaghar A, Amin-Esmaeili M, Sharifi V, Hajebi A, Radgoodarzi R, Hefazi M, et al. Iranian mental health survey: design and field proced. Iran J Psychiatry. 2014;9(2):96-109. [PubMed ID: 25632287]. [PubMed Central ID: PMC4300472].
16.
Davarinejad O, Mohammadi Majd T, Golmohammadi F, Mohammadi P, Radmehr F, Alikhani M, et al. Identification of Risk Factors to Predict the Occurrences of Relapses in Individuals with Schizophrenia Spectrum Disorder in Iran. Int J Environ Res Public Health. 2021;18(2):546. [PubMed ID: 33440817]. [PubMed Central ID: PMC7827717]. https://doi.org/10.3390/ijerph18020546.
17.
Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, et al. Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016. Schizophr Bull. 2018;44(6):1195-203. [PubMed ID: 29762765]. [PubMed Central ID: PMC6192504]. https://doi.org/10.1093/schbul/sby058.
18.
Kirakosyan G, Frolova A. Understanding psychosis: treatment and rehabilitation (updates for clinicians). World J Adv Res Rev. 2022;13(1):115–121. https://doi.org/10.30574/wjarr.2022.13.1.0006.
19.
McGregor N, Thompson N, O'Connell KS, Emsley R, van der Merwe L, Warnich L. Modification of the association between antipsychotic treatment response and childhood adversity by MMP9 gene variants in a first-episode schizophrenia cohort. Psychiatry Res. 2018;262:141-8. [PubMed ID: 29448178]. https://doi.org/10.1016/j.psychres.2018.01.044.
20.
Bachmann S, Resch F, Mundt C. Psychological Treatments for Psychosis: History and Overview. Psychodyn Psychiatry. 2022;50(1):24-42. [PubMed ID: 35235398]. https://doi.org/10.1521/pdps.2022.50.1.24.
21.
Chernov NV, Moiseeva TV, Belyakova MA, Polyakova MD, Sozinova MV. Acceptance and Commitment Therapy for Patients with a First Psychotic Episode. Consortium Psychiatricum. 2021;2(4):30-9. https://doi.org/10.17816/cp97.
22.
McLeod HJ. ACT and CBT for psychosis: Comparisons and contrasts. Acceptance and commitment therapy: Contemporary theory research and practice. Australian Academic Press; 2009. p. 263-279.
23.
White R, Gumley A, McTaggart J, Rattrie L, McConville D, Cleare S, et al. A feasibility study of Acceptance and Commitment Therapy for emotional dysfunction following psychosis. Behav Res Ther. 2011;49(12):901-7. [PubMed ID: 21975193]. https://doi.org/10.1016/j.brat.2011.09.003.
24.
Cramer H, Lauche R, Haller H, Langhorst J, Dobos G. Mindfulness- and Acceptance-based Interventions for Psychosis: A Systematic Review and Meta-analysis. Glob Adv Health Med. 2016;5(1):30-43. [PubMed ID: 26937312]. [PubMed Central ID: PMC4756771]. https://doi.org/10.7453/gahmj.2015.083.
25.
Larsson C, Fatouros-Bergman H, Isaksson A, Johansson M, Kaldo V, Parling T, et al. Acceptance and Commitment Therapy for inpatients with psychosis –an acceptability and feasibility single case AB designed study. J Contextual Behav Sci. 2022;25:44-60. https://doi.org/10.1016/j.jcbs.2022.05.008.
26.
Shawyer F, Farhall J, Thomas N, Hayes SC, Gallop R, Copolov D, et al. Acceptance and commitment therapy for psychosis: randomised controlled trial. Br J Psychiatry. 2017;210(2):140-8. [PubMed ID: 27979820]. https://doi.org/10.1192/bjp.bp.116.182865.
27.
Spidel A, Lecomte T, Kealy D, Daigneault I. Acceptance and commitment therapy for psychosis and trauma: Improvement in psychiatric symptoms, emotion regulation, and treatment compliance following a brief group intervention. Psychol Psychother. 2018;91(2):248-61. [PubMed ID: 28976056]. https://doi.org/10.1111/papt.12159.
28.
Zuidersma M, Riese H, Snippe E, Booij SH, Wichers M, Bos EH. Single-Subject Research in Psychiatry: Facts and Fictions. Front Psychiatry. 2020;11:1174. [PubMed ID: 33281636]. [PubMed Central ID: PMC7691231]. https://doi.org/10.3389/fpsyt.2020.539777.
29.
Voigt ALA, Kreiter DJ, Jacobs CJ, Revenich EGM, Serafras N, Wiersma M, et al. Clinical Network Analysis in a Bipolar Patient Using an Experience Sampling Mobile Health Tool: An n=1 Study. Bipolar Disord: Open Access. 2018;4(1). https://doi.org/10.4172/2472-1077.1000121.
30.
Fisher AJ, Bosley HG, Fernandez KC, Reeves JW, Soyster PD, Diamond AE, et al. Open trial of a personalized modular treatment for mood and anxiety. Behav Res Ther. 2019;116:69-79. [PubMed ID: 30831478]. https://doi.org/10.1016/j.brat.2019.01.010.
31.
Khoury B, Lecomte T. Emotion Regulation and Schizophrenia. Int J Cogn Ther. 2012;5(1):67-76. https://doi.org/10.1521/ijct.2012.5.1.67.
32.
Wakefield S, Roebuck S, Boyden P. The evidence base of Acceptance and Commitment Therapy (ACT) in psychosis: A systematic review. J Contextual Behav Sci. 2018;10:1-13. https://doi.org/10.1016/j.jcbs.2018.07.001.
33.
Horner RH, Carr EG, Halle J, McGee G, Odom S, Wolery M. The Use of Single-Subject Research to Identify Evidence-Based Practice in Special Education. Except Child. 2016;71(2):165-79. https://doi.org/10.1177/001440290507100203.
34.
Kazdin AE. Single-case experimental designs. Evaluating interventions in research and clinical practice. Behav Res Ther. 2019;117:3-17. [PubMed ID: 30527785]. https://doi.org/10.1016/j.brat.2018.11.015.
35.
Morgan TA, Dalrymple K, D'Avanzato C, Zimage S, Balling C, Ward M, et al. Conducting Outcomes Research in a Clinical Practice Setting: The Effectiveness and Acceptability of Acceptance and Commitment Therapy (ACT) in a Partial Hospital Program. Behav Ther. 2021;52(2):272-85. [PubMed ID: 33622499]. https://doi.org/10.1016/j.beth.2020.08.004.
36.
Horner RH, Odom SL. Constructing single-case research designs: Logic and options. Single-case intervention research: Methodological and statistical advances. American Psychological Association; 2014. 27–51 p.
37.
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76. [PubMed ID: 3616518]. https://doi.org/10.1093/schbul/13.2.261.
38.
Abolghasemi A. [The relationship of meta-cognitive beliefs with positive and negative symptomes in the schizophrenia patients]. Clin Psychol Pers. 2007;5(2):1-10. Persian.
39.
Ghamari Givi H, Moulavi P, Heshmati R. Exploration of the factor structure of positive and negative syndrome scale in schizophernia spectrum disorder. J Clin Psychol. 2010;2(2):1-10.
40.
Mirzaei M, Gharraee B, Birashk B. The role of positive and negative perfectionism, self-efficacy, worry and emotion regulation in predicting behavioral and decisional procrastination. Iran J Psychiatry Clin Psychol. 2013;19(3).
41.
Gratz KL, Roemer L. Multidimensional Assessment of Emotion Regulation and Dysregulation: Development, Factor Structure, and Initial Validation of the Difficulties in Emotion Regulation Scale. J Psychopathol Behav Assess. 2004;26:41–54. https://doi.org/10.1023/B:JOBA.0000007455.08539.94.
42.
Asgari P, Pasha Gh R, Aminiyan M. Relationship between emotion regulation, mental stresses and body image with eating disorders of women. Thought Behav Clin Psychol. 2009;4(13):65-78.
43.
Mazloom M. The relationship of metacognitive beliefs and emotion regulation difficulties with post traumatic stress disorder. Int J Behav Sci. 2014;8(2):105-13.
44.
Morris EM, Johns LC, Oliver JE. Acceptance and commitment therapy and mindfulness for psychosis. John Wiley & Sons; 2013.
45.
Ferguson CJ. An effect size primer: a guide for clinicians and researchers. Prof Psychol Res Pract. 2016;40(5):532–538. https://doi.org/10.1037/a0015808.
46.
Hayes SC. Acceptance and Commitment Therapy, Relational Frame Theory, and the Third Wave of Behavioral and Cognitive Therapies - Republished Article. Behav Ther. 2016;47(6):869-85. [PubMed ID: 27993338]. https://doi.org/10.1016/j.beth.2016.11.006.
47.
Goldstone E, Farhall J, Ong B. Life hassles, experiential avoidance and distressing delusional experiences. Behav Res Ther. 2011;49(4):260-6. [PubMed ID: 21377651]. https://doi.org/10.1016/j.brat.2011.02.002.
48.
Yildiz E. The effects of acceptance and commitment therapy in psychosis treatment: A systematic review of randomized controlled trials. Perspect Psychiatr Care. 2020;56(1):149-67. [PubMed ID: 31074039]. https://doi.org/10.1111/ppc.12396.
49.
Louise S, Fitzpatrick M, Strauss C, Rossell SL, Thomas N. Mindfulness- and acceptance-based interventions for psychosis: Our current understanding and a meta-analysis. Schizophr Res. 2018;192:57-63. [PubMed ID: 28545945]. https://doi.org/10.1016/j.schres.2017.05.023.
50.
Villatte JL, Vilardaga R, Villatte M, Plumb Vilardaga JC, Atkins DC, Hayes SC. Acceptance and Commitment Therapy modules: Differential impact on treatment processes and outcomes. Behav Res Ther. 2016;77:52-61. [PubMed ID: 26716932]. [PubMed Central ID: PMC4752868]. https://doi.org/10.1016/j.brat.2015.12.001.
51.
Gaudiano BA, Herbert JD, Hayes SC. Is it the symptom or the relation to it? Investigating potential mediators of change in acceptance and commitment therapy for psychosis. Behav Ther. 2010;41(4):543-54. [PubMed ID: 21035617]. [PubMed Central ID: PMC3673289]. https://doi.org/10.1016/j.beth.2010.03.001.
52.
Tyrberg MJ, Carlbring P, Lundgren T. Brief acceptance and commitment therapy for psychotic inpatients: A randomized controlled feasibility trial in Sweden. Nordic Psychology. 2016;69(2):110-25. https://doi.org/10.1080/19012276.2016.1198271.

comments